[en] Signaling pathways mediating the antiangiogenic action of 16K human (h)PRL include inhibition of vascular endothelial growth factor (VEGF)-induced activation of the mitogen-activated protein kinases (MAPK). To determine at which step 16K hPRL acts to inhibit VEGF-induced MAPK activation, we assessed more proximal events in the signaling cascade. 16K hPRL treatment blocked VEGF-induced Raf-1 activation as well as its translocation to the plasma membrane. 16K hPRL indirectly increased cAMP levels; however, the blockade of Raf-1 activation was not dependent on the stimulation of cAMP-dependent protein kinase (PKA), but rather on the inhibition of the GTP-bound Ras. The VEGF-induced tyrosine phosphorylation of the VEGF receptor, Flk-1, and its association with the Shc/Grb2/Ras-GAP (guanosine triphosphatase-activating protein) complex were unaffected by 16K hPRL treatment. In contrast, 16K hPRL prevented the VEGF-induced phosphorylation and dissociation of Sos from Grb2 at 5 min, consistent with inhibition by 16K hPRL of the MEK/MAPK feedback on Sos. The inhibition of Ras activation was paralleled by the increased phosphorylation of 120 kDa proteins comigrating with Ras-GAP. Taken together, these findings show that 16K hPRL inhibits the VEGF-induced Ras activation; this antagonism represents a novel and potentially important mechanism for the control of angiogenesis.
Disciplines :
Biochemistry, biophysics & molecular biology
Author, co-author :
D'Angelo, Gisela; Université de Liège - ULiège > Département des sciences de la vie > GIGA-R : Biologie et génétique moléculaire
Hanahan D., Folkman J. (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-364.
Folkman J. (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1:27-31.
Esch F., Baird A., Ling N., Ueno N., Hill F., Denoroy L., Klepper R., Gospodarowicz D., Bohlen P., Guillemin R. (1985) Primary structure of bovine pituitary basic fibroblast growth factor (FGF) and comparison with the amino-terminal sequence of bovine brain acidic FGF. Proc Natl Acad Sci USA 82:6507-6511.
Ferrara N., Henzel W.J. (1989) Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 161:851-858.
Connolly D.T., Olander J.V., Heuvelman D., Nelson R., Monsell R., Siegel N., Haymore B.L., Leimgruber R., Feder J. (1989) Human vascular permeability factor. Isolation from U937 cells. J Biol Chem 264:20017-20024.
Ferrara N., Clapp C., Weiner R. (1991) The 16K fragment of prolactin specifically inhibits basal or fibroblast growth factor stimulated growth of capillary endothelial cells. Endocrinology 129:896-900.
Clapp C., Martial J.A., Guzman R.C., Rentier-Delure F., Weiner R.I. (1993) The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis. Endocrinology 133:1292-1299.
Good D.J., Polverini P.J., Rastinejad F., Le Beau M.M., Lemons R.S., Frazier W.A., Bouck N.P. (1990) A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA 87:6624-6628.
Maione T.E., Gray G.S., Petro J., Hunt A.J., Donner A.L., Bauer S.I., Carson H.F., Sharpe R.J. (1990) Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 247:77-79.
O'Reilly M.S., Holmgren L., Shing Y., Chen C., Rosenthal R.A., Moses M., Lane W.S., Cao Y., Sage E.H., Folkman J. (1994) Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79:315-328.
O'Reilly M.S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W.S., Flynn E., Birkhead J.R., Olsen B.R., Folkman J. (1997) Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277-285.
Lee P.L., Johnson D.E., Cousens L.S., Fried V.A., Williams L.T. (1989) Purification and complementary DNA cloning of a receptor for basic fibroblast growth factor. Science 245:57-60.
De Vries C., Escobedo J.A., Ueno H., Houck K., Ferrara N., Williams L.T. (1992) The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255:989-991.
Ullrich A., Schlessinger J. (1990) Signal transduction by receptors with tyrosine kinase activity. Cell 61:203-212.
Lowenstein E.J., Daly R.J., Batzer A.G., Li W., Margolis B., Lammers R., Ullrich A., Skolnik E.Y., Bar-Sagi D., Schlessinger J. (1992) The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling. Cell 70:431-442.
Pelicci G., Lanfrancone L., Grignani F., McGlade J., Cavallo F., Forni G., Nicoletti I., Grignani F., Pawson T., Pelicci P.G. (1992) A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction. Cell 70:93-104.
Rozakis-Adcock M., Fernley R., Wade J., Pawson T., Bowtell D. (1993) The SH2 and SH3 domains of mammalian Grb2 couple the EGF receptor to the Ras activator mSos1. Nature 363:83-85.
Trahey M., McCormick F. (1987) A cytoplasmic protein stimulates normal N-ras p21 GTPase, but does not affect oncogenic mutants. Science 238:542-545.
Kroll J., Waltenberger J. (1997) The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells. J Biol Chem 272:32521-32527.
Guo D., Jia Q., Song H.Y., Warren R.S., Donner D.B. (1995) Vascular endothelial cell growth factor promotes tyrosine phosphorylation of mediators of signal transduction that contain SH2 domains. Association with endothelial cell proliferation. J Biol Chem 270:6729-6733.
D'Angelo G., Lee H., Weiner R.I. (1997) cAMP-dependent protein kinase inhibits the mitogenic action of vascular endothelial growth factor and fibroblast growth factor in capillary endothelial cells by blocking Raf activation. J Cell Biochem 67:353-366.
D'Angelo G., Struman I., Martial J., Weiner R.I. (1995) Activation of mitogen-activated protein kinases by vascular endothelial growth factor and basic fibroblast growth factor in capillary endothelial cells is inhibited by the antiangiogenic factor 16-kDa N-terminal fragment of prolactin. Proc Natl Acad Sci USA 92:6374-6378.
Cook S.J., McCormick F. (1993) Inhibition by cAMP of Ras-dependent activation of Raf. Science 262:1069-1072.
Wu J., Dent P., Jelinek T., Wolfman A., Weber M.J., Sturgill T.W. (1993) Inhibition of the EGF-activated MAP kinase signaling pathway by adenosine 3',5'-monophosphate. Science 262:1065-1069.
Chabre O., Cornillon F., Bottari S.P., Chambaz E.M., Vilgrain I. (1995) Hormonal regulation of mitogen-activated protein kinase activity in bovine adrenocortical cells: Cross-talk between phosphoinositides, adenosine 3',5'-monophosphate, and tyrosine kinase receptor pathways. Endocrinology 136:956-964.
Clapp C., Weiner R.I. (1992) A specific, high affinity, saturable binding site for the 16-kilodalton fragment of prolactin on capillary endothelial cells. Endocrinology 130:1380-1386.
Stokoe D., Macdonald S.G., Cadwallader K., Symons M., Hancock J.F. (1994) Activation of Raf as a result of recruitment to the plasma membrane. Science 264:1463-1467.
Macdonald S.G., Crews C.M., Wu L., Driller J., Clark R., Erikson R.L., McCormick F. (1993) Reconstitution of the Raf-1-MEK-ERK signal transduction pathway in vitro. Mol Cell Biol 13:6615-6620.
Chijiwa T., Mishima A., Hagiwara M., Sano M., Hayashi K., Inoue T., Naito K., Toshioka T., Hidaka H. (1990) Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells. J Biol Chem 265:5267-5272.
Leevers S.J., Paterson H.F., Marshall C.J. (1994) Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane. Nature 369:411-414.
Prouty S.M., Maroo A., Maucher C., Mischak H., Kolch W., Sedivy J.M. (1998) Studies of perinuclear and nuclear translocation of the Raf-1 protein in rodent fibroblasts. Biochim Biophys Acta 1402:6-16.
Burgering B.M., Bos J.L. (1995) Regulation of Ras-mediated signalling: More than one way to skin a cat. Trends Biochem Sci 20:18-22.
Chardin P., Camonis J.H., Gale N.W., Van Aelst L., Schlessinger J., Wigler M.H., Bar-Sagi D. (1993) Human Sos1: A guanine nucleotide exchange factor for Ras that binds to GRB2. Science 260:1338-1343.
Waters S.B., Yamauchi K., Pessin J.E. (1995) Insulin-stimulated disassociation of the SOS-Grb2 complex. Mol Cell Biol 15:2791-2799.
Dong C., Waters S.B., Holt K.H., Pessin J.E. (1996) SOS phosphorylation and disassociation of the Grb2-SOS complex by the ERK and JNK signaling pathways. J Biol Chem 271:6328-6332.
Tamada M., Hu C.D., Kariya K., Okada T., Kataoka T. (1997) Membrane recruitment of Raf-1 is not the only function of Ras in Raf-1 activation. Oncogene 15:2959-2964.
Cherniack A.D., Klarlund J.K., Czech M.P. (1994) Phosphorylation of the Ras nucleotide exchange factor son of sevenless by mitogen-activated protein kinase. J Biol Chem 269:4717-4720.
Holt K.H., Kasson B.G., Pessin J.E. (1996) Insulin stimulation of a MEK-dependent but ERK-independent SOS protein kinase. Mol Cell Biol 16:577-583.
Hu Y., Bowtell D.D. (1996) Sos1 rapidly associates with Grb2 and is hypophosphorylated when complexed with the EGF receptor after EGF stimulation. Oncogene 12:1865-1872.
Boguski M.S., McCormick F. (1993) Proteins regulating Ras and its relatives. Nature 366:643-654.
Tocque B., Delumeau I., Parker F., Maurier F., Multon M.C., Schweighoffer F. (1997) Ras-GTPase activating protein (GAP): A putative effector for Ras. Cell Signal 9:153-158.
Borowski P., Kornetzky L., Heiland M., Roloff S., Weber W., Laufs R. (1996) Characterization of the C-terminal domain of ras-GTPase-activating protein (ras-GAP) as substrate for epidermal growth factor receptor and p60c-src kinase. Biochem Mol Biol Int 39:635-646.
Park S., Liu X., Pawson T., Jove R. (1992) Activated Src tyrosine kinase phosphorylates Tyr-457 of bovine GTPase-activating protein (GAP) in vitro and the corresponding residue of rat GAP in vivo. J Biol Chem 267:17194-17200.
Jefferson A.B., Klippel A., Williams L.T. (1998) Inhibition of mSOS-activity by binding of phosphatidylinositol 4,5-P2 to the mSOS pleckstrin homology domain. Oncogene 16:2303-2310.
Ellis C., Moran M., McCormick F., Pawson T. (1990) Phosphorylation of GAP and GAP-associated proteins by transforming and mitogenic tyrosine kinases. Nature 343:377-381.
Lee H., Struman I., Clapp C., Martial J., Weiner R.I. (1998) Inhibition of urokinase activity by the antiangiogenic factor 16K prolactin: Activation of plasminogen activator inhibitor 1 expression. Endocrinology 139:3696-3703.
Martini J.F., Piot C., Wolf C.L., Weiner R.I. (1997) Antiangiogenic action of 16K hPRL involves activation of apoptosis. Mol Biol Cell , Abstract; 8(SUPPL.).
Paris N., Rentier-Delrue F., Defontaine A., Goffin V., Lebrun J.J., Mercier L., Martial J.A. (1990) Bacterial production and purification of recombinant human prolactin. Biotechnol Appl Biochem 12:436-449.
Cooke N.E., Colt D., Shine J., Baxter J.D., Martial J.A. (1981) Human prolactin. cDNA structural analysis and evolutionary comparisons. J Biol Chem 256:4007-4016.
Gospodarowicz D., Cheng J. (1986) Heparin protects basic and acidic FGF from inactivation. J Cell Physiol 128:475-484.
Crews C.M., Erikson R.L. (1992) Purification of a murine protein-tyrosine/threonine kinase that phosphorylates and activates the Erk-1 gene product: Relationship to the fission yeast byr1 gene product. Proc Natl Acad Sci USA 89:8205-8209.
Brooker G., Harper J.F., Terasaki W.L., Moylan R.D. (1979) Radioimmunoassay of cyclic AMP and cyclic GMP. Adv Cyclic Nucleotide Res 10:1-33.
Ross E.M., Maguire M.E., Sturgill T.W., Biltonen R.L., Gilman A.G. (1977) Relationship between the beta-adrenergic receptor and adenylate cyclase. J Biol Chem 252:5761-5775.
Salomon Y., Londos C., Rodbell M. (1974) A highly sensitive adenylate cyclase assay. Anal Biochem 58:541-548.
Downward J., Graves J.D., Warne P.H., Rayter S., Cantrell D.A. (1990) Stimulation of p21ras upon T-cell activation. Nature 346:719-723.